Drug Discovery for Paediatric Chagas Disease

Mini Rev Med Chem. 2018;18(9):776-780. doi: 10.2174/1389557516666161226155204.

Abstract

Chagas disease is caused by the parasite Trypanosoma cruzi and is regularly found among particular people living in Central and South America. Paediatric Chagas disease occurs in 1-10% of infants of infected mothers. The major important point considered in the treatment of congenital Chagas disease focuses on killing the parasite in acute infection and managing signs and symptoms in later stages. Nowadays, two drugs benznidazole and nifurtimox are currently available in the market for the treatment of paediatric Chagas disease.

Keywords: Chagas disease; Trypanosoma cruzi; congenital; infants; symptoms; treatment..

Publication types

  • Review

MeSH terms

  • Antiparasitic Agents / chemical synthesis
  • Antiparasitic Agents / chemistry
  • Antiparasitic Agents / pharmacology*
  • Chagas Disease / drug therapy*
  • Chagas Disease / parasitology*
  • Drug Discovery*
  • Humans
  • Nifurtimox / chemical synthesis
  • Nifurtimox / chemistry
  • Nifurtimox / pharmacology*
  • Nitroimidazoles / chemical synthesis
  • Nitroimidazoles / chemistry
  • Nitroimidazoles / pharmacology*
  • Parasitic Sensitivity Tests
  • Trypanosoma cruzi / drug effects*

Substances

  • Antiparasitic Agents
  • Nitroimidazoles
  • Nifurtimox
  • benzonidazole